Long-term effects of high-dose zidovudine treatment on neuropsychological performance in mildly symptomatic HIV-positive patients: Results of a randomized, double-blind, placebo-controlled investigation

Antolin M. Llorente, Wilfred G. Van Gorp, Martin J. Stern, Lance George, Paul Satz, Thomas D. Marcotte, Gilbert M. Calvillo, Charles H. Hinkin

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

This study examined the treatment outcome of high-dose (1500 mg/day) zidovudine (AZT) on neuropsychological (NP) functioning (Trailmaking Test A & B, WAIS-R Digit Symbol, and Rey Auditory Verbal Learning Test) across a 12-month period in mildly symptomatic HIV-1 seropositive men (n = 46 at entry) enrolled in a randomized, double-blind, placebo-controlled trial (VA Cooperative Studies Program #298). Neither short-term (0-6 months) nor long-term (0-12 months) AZT administration revealed enhancement in NP performance. The results suggest that, although AZT may afford patients prophylactic benefits, protracted high-dose AZT treatment does not improve NP functioning in mildly symptomatic HIV-positive individuals.

Original languageEnglish (US)
Pages (from-to)27-32
Number of pages6
JournalJournal of the International Neuropsychological Society
Volume7
Issue number1
DOIs
StatePublished - 2001

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Clinical Psychology
  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Long-term effects of high-dose zidovudine treatment on neuropsychological performance in mildly symptomatic HIV-positive patients: Results of a randomized, double-blind, placebo-controlled investigation'. Together they form a unique fingerprint.

Cite this